Hudson Bay Capital Management
APGE icon

Hudson Bay Capital Management’s Apogee Therapeutics APGE Stock Holding History

Hudson Bay Capital Management’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-79,000
Closed -$5.96M – 1390
2025
Q4 		$5.96M Buy
+79,000
New +$4.98M 0.02% 457

Other funds holding APGE

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Hudson Bay Capital Management's APGE Position: Q1 2026 in Review

Hudson Bay Capital Management opened a new position in Apogee Therapeutics (APGE) in Q1 2026: 5,720 shares worth $481K. The stake represents ﹤0.01% of the portfolio and ranks #982 among its holdings. This is a return to the name: Hudson Bay Capital Management previously reported a position in APGE as recently as Q4 2023.

Hudson Bay Capital Management first reported a position in APGE in Q4 2023 and has held it in 2 quarters since. The position peaked at $559K in Q4 2023. 224 funds tracked by Wall St. Rank hold APGE as of Q1 2026.

  • Hudson Bay Capital Management held 5,720 shares of Apogee Therapeutics worth $481K as of Q1 2026.
  • Apogee Therapeutics was a new Hudson Bay Capital Management position in Q1 2026.
  • Apogee Therapeutics made up ﹤0.01% of Hudson Bay Capital Management's portfolio in Q1 2026, its #982 holding.
  • Hudson Bay Capital Management first reported a position in Apogee Therapeutics in Q4 2023 and has held it in 2 quarters since.
  • Hudson Bay Capital Management's Apogee Therapeutics position peaked at $559K in Q4 2023.
  • 224 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q1 2026.

Based on Hudson Bay Capital Management's 13F filing for Q1 2026, filed 13 May 2026.